CRL Quote, Financials, Valuation and Earnings

Eli Lilly & Co. has a net margin of 5.53% compared to Charles River Laboratories International, Inc.'s net margin of 31.72%. Charles River Laboratories International, Inc.'s return on equity of -2.28% beat Eli Lilly & Co.'s return on equity of 106.26%.

Charles River Laboratories International, Inc. has a consensus price target of $200.67, signalling downside risk potential of -7.43%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,098.04 which suggests that it could fall by -0.91%. Given that Charles River Laboratories International, Inc. has more downside risk than Eli Lilly & Co., analysts believe Eli Lilly & Co. is more attractive than Charles River Laboratories International, Inc..

Charles River Laboratories International, Inc. has a beta of 1.613, which suggesting that the stock is 61.299% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Charles River Laboratories International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.54% to investors and pays a quarterly dividend of $1.50 per share. Charles River Laboratories International, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Charles River Laboratories International, Inc. quarterly revenues are $1B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Charles River Laboratories International, Inc.'s net income of $55.6M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Charles River Laboratories International, Inc.'s price-to-earnings ratio is 913.13x while Eli Lilly & Co.'s PE ratio is 54.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International, Inc. is 2.70x versus 17.00x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 5.53% compared to Charles River Laboratories International, Inc.'s net margin of 38.89%. Charles River Laboratories International, Inc.'s return on equity of -2.28% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Charles River Laboratories International, Inc. has a consensus price target of $200.67, signalling downside risk potential of -7.43%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $804.96 which suggests that it could fall by -0.9%. Given that Charles River Laboratories International, Inc. has more downside risk than Regeneron Pharmaceuticals, Inc., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Charles River Laboratories International, Inc..

Charles River Laboratories International, Inc. has a beta of 1.613, which suggesting that the stock is 61.299% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.

Charles River Laboratories International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.43% to investors and pays a quarterly dividend of $0.88 per share. Charles River Laboratories International, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Charles River Laboratories International, Inc. quarterly revenues are $1B, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Charles River Laboratories International, Inc.'s net income of $55.6M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Charles River Laboratories International, Inc.'s price-to-earnings ratio is 913.13x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 19.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International, Inc. is 2.70x versus 6.28x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bio-Techne Corp. has a net margin of 5.53% compared to Charles River Laboratories International, Inc.'s net margin of 13.32%. Charles River Laboratories International, Inc.'s return on equity of -2.28% beat Bio-Techne Corp.'s return on equity of 3.85%.

Charles River Laboratories International, Inc. has a consensus price target of $200.67, signalling downside risk potential of -7.43%. On the other hand Bio-Techne Corp. has an analysts' consensus of $69.17 which suggests that it could grow by 6.33%. Given that Bio-Techne Corp. has higher upside potential than Charles River Laboratories International, Inc., analysts believe Bio-Techne Corp. is more attractive than Charles River Laboratories International, Inc..

Charles River Laboratories International, Inc. has a beta of 1.613, which suggesting that the stock is 61.299% more volatile than S&P 500. In comparison Bio-Techne Corp. has a beta of 1.470, suggesting its more volatile than the S&P 500 by 47.016%.

Charles River Laboratories International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bio-Techne Corp. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.08 per share. Charles River Laboratories International, Inc. pays -- of its earnings as a dividend. Bio-Techne Corp. pays out 69.67% of its earnings as a dividend. Bio-Techne Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Charles River Laboratories International, Inc. quarterly revenues are $1B, which are larger than Bio-Techne Corp. quarterly revenues of $286.6M. Charles River Laboratories International, Inc.'s net income of $55.6M is higher than Bio-Techne Corp.'s net income of $38.2M. Notably, Charles River Laboratories International, Inc.'s price-to-earnings ratio is 913.13x while Bio-Techne Corp.'s PE ratio is 132.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International, Inc. is 2.70x versus 8.43x for Bio-Techne Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Thermo Fisher Scientific, Inc. has a net margin of 5.53% compared to Charles River Laboratories International, Inc.'s net margin of 14.58%. Charles River Laboratories International, Inc.'s return on equity of -2.28% beat Thermo Fisher Scientific, Inc.'s return on equity of 13.15%.

Charles River Laboratories International, Inc. has a consensus price target of $200.67, signalling downside risk potential of -7.43%. On the other hand Thermo Fisher Scientific, Inc. has an analysts' consensus of $646.43 which suggests that it could grow by 3.96%. Given that Thermo Fisher Scientific, Inc. has higher upside potential than Charles River Laboratories International, Inc., analysts believe Thermo Fisher Scientific, Inc. is more attractive than Charles River Laboratories International, Inc..

Charles River Laboratories International, Inc. has a beta of 1.613, which suggesting that the stock is 61.299% more volatile than S&P 500. In comparison Thermo Fisher Scientific, Inc. has a beta of 0.907, suggesting its less volatile than the S&P 500 by 9.346%.

Charles River Laboratories International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Thermo Fisher Scientific, Inc. offers a yield of 0.28% to investors and pays a quarterly dividend of $0.43 per share. Charles River Laboratories International, Inc. pays -- of its earnings as a dividend. Thermo Fisher Scientific, Inc. pays out 9.43% of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Charles River Laboratories International, Inc. quarterly revenues are $1B, which are smaller than Thermo Fisher Scientific, Inc. quarterly revenues of $11.1B. Charles River Laboratories International, Inc.'s net income of $55.6M is lower than Thermo Fisher Scientific, Inc.'s net income of $1.6B. Notably, Charles River Laboratories International, Inc.'s price-to-earnings ratio is 913.13x while Thermo Fisher Scientific, Inc.'s PE ratio is 35.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International, Inc. is 2.70x versus 5.36x for Thermo Fisher Scientific, Inc.. Usually stocks with elevated PS ratios are considered overvalued.